-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the release of a series of favorable pharmaceutical innovation policies, the domestic innovative drug industry has ushered in vigorous development, and the strength of local enterprises has been continuously improved, gradually from introducing (license in) to going out (license out) ), the overseas transactions of domestic innovative drugs are becoming more and more freque.
On August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022 to conduct ( China includes mainland China, Hong Kong, Macau and Taiwan) regional research, development, manufacturing and commercializati.
This is not the first time Colombo has partnered with M.
In July this year, Colombo just announced that it will license its biomacromolecule tumor project B with independent intellectual property rights to MSD for global research, development, manufacturing and commercializati.
This cooperation means that the license out transaction of Kelun Pharmaceuticals will be another succe.
For the SKB264 program, MSD and Colombo will collaborate on certain early-stage clinical development programs, including evaluating the potential of SKB-264 as a monotherapy and in combination with Keytruda in advanced solid tumo.
The announcement shows that Colombo has received from MSD on June 24, 2022 a license fee of US$30 million for Project A (the actual amount received is subject to deduction of withholding taxes calculated in accordance with relevant laws and bank procedure.
fe.
Colombo will also receive a one-time payment of $30 million and $25 million upon completion of certain development activities and upon completion of certain technology transfers, respective.
MSD agreed to make quarterly payments totaling $101 million to Colombo in 2022 and 2023 to fund Colombo's ongoing research and development activities for SKB264 (additionally, Colombo received in November 2021 $17 million also falls into this categor.
In addition, MSD will pay Colombo Technologies cumulative development milestones of up to $90 million, first commercial sales milestones of $290 million, and sales milestones of $780 million, based on the development stage, and a mid-single-digit share based on net sales range to low double-digit net sal.
In the past, the license-in model was considered to be a "shortcut" for biopharmaceutical companies to overtake in corne.
In recent years, the number and amount of domestic innovative drugs participating in license-in transactions continued to ri.
Among them, only in the first half of 2021, the disclosed pharmaceutical companies' license-in transactions Among the transactions, there are nearly 20 transactions with a transaction value of more than 100 million US dolla.
However, returning to itself, the lack of original innovation capabilities of local pharmaceutical companies is still a major shortcomi.
In July 2021, the National Center for Drug Evaluation issued the "Guiding Principles for Clinical Value-Oriented Clinical Research and Development of Anti-tumor Drugs" for public solicitati.
"Pseudo-innovation" problem, the quality of local innovative drugs needs to be improv.
With the advancement of new medical reform policies such as centralized procurement and generic drug consistency evaluation, Chinese pharmaceutical companies are gradually transforming from generic drugs to innovative dru.
R&D investment has continued to increase, innovation strength has continued to improve, and the number of license out transactions has also increas.
situati.
Among them, Rongchang Bio's Vidicitumumab (RC48) is more concerned, which will be paid in August 2021 with a down payment of $200 million and a milestone payment of up to $4 billion, and future payments from high single digits The development and commercialization rights other than the Greater China region will be licensed to Seagen in the United States for a sales commission of more than ten perce.
Also of interest is BeiGene's rights to tislelizumab, which has been licensed to Novartis in key global markets excluding China, with an upfront payment of $650 million and a total transaction value of more than $2 billi.
The industry believes that from the perspective of the license out projects of domestic innovative drug companies, mainly tumor drugs are the main on.
The gap between pharmaceutical companies and large international pharmaceutical companies is narrowi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
On August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022 to conduct ( China includes mainland China, Hong Kong, Macau and Taiwan) regional research, development, manufacturing and commercializati.
This is not the first time Colombo has partnered with M.
In July this year, Colombo just announced that it will license its biomacromolecule tumor project B with independent intellectual property rights to MSD for global research, development, manufacturing and commercializati.
This cooperation means that the license out transaction of Kelun Pharmaceuticals will be another succe.
For the SKB264 program, MSD and Colombo will collaborate on certain early-stage clinical development programs, including evaluating the potential of SKB-264 as a monotherapy and in combination with Keytruda in advanced solid tumo.
The announcement shows that Colombo has received from MSD on June 24, 2022 a license fee of US$30 million for Project A (the actual amount received is subject to deduction of withholding taxes calculated in accordance with relevant laws and bank procedure.
fe.
Colombo will also receive a one-time payment of $30 million and $25 million upon completion of certain development activities and upon completion of certain technology transfers, respective.
MSD agreed to make quarterly payments totaling $101 million to Colombo in 2022 and 2023 to fund Colombo's ongoing research and development activities for SKB264 (additionally, Colombo received in November 2021 $17 million also falls into this categor.
In addition, MSD will pay Colombo Technologies cumulative development milestones of up to $90 million, first commercial sales milestones of $290 million, and sales milestones of $780 million, based on the development stage, and a mid-single-digit share based on net sales range to low double-digit net sal.
In the past, the license-in model was considered to be a "shortcut" for biopharmaceutical companies to overtake in corne.
In recent years, the number and amount of domestic innovative drugs participating in license-in transactions continued to ri.
Among them, only in the first half of 2021, the disclosed pharmaceutical companies' license-in transactions Among the transactions, there are nearly 20 transactions with a transaction value of more than 100 million US dolla.
However, returning to itself, the lack of original innovation capabilities of local pharmaceutical companies is still a major shortcomi.
In July 2021, the National Center for Drug Evaluation issued the "Guiding Principles for Clinical Value-Oriented Clinical Research and Development of Anti-tumor Drugs" for public solicitati.
"Pseudo-innovation" problem, the quality of local innovative drugs needs to be improv.
With the advancement of new medical reform policies such as centralized procurement and generic drug consistency evaluation, Chinese pharmaceutical companies are gradually transforming from generic drugs to innovative dru.
R&D investment has continued to increase, innovation strength has continued to improve, and the number of license out transactions has also increas.
situati.
Among them, Rongchang Bio's Vidicitumumab (RC48) is more concerned, which will be paid in August 2021 with a down payment of $200 million and a milestone payment of up to $4 billion, and future payments from high single digits The development and commercialization rights other than the Greater China region will be licensed to Seagen in the United States for a sales commission of more than ten perce.
Also of interest is BeiGene's rights to tislelizumab, which has been licensed to Novartis in key global markets excluding China, with an upfront payment of $650 million and a total transaction value of more than $2 billi.
The industry believes that from the perspective of the license out projects of domestic innovative drug companies, mainly tumor drugs are the main on.
The gap between pharmaceutical companies and large international pharmaceutical companies is narrowi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
